2[1]Ishida T,Hashimoto M,Arita I,et al.Etiology of community-acquired pneumonia in hospitalized patients:a 3-year prospective study in Japan.Chest,1998,114(6):1588-1593
3[3]Lucier TS,Heitzman K,Liu SK,et al.Transition mutations in the 23SrRNA of erythromycin-resistant isolates of Mycoplasma pneumonia.Antimicrob Agents Chemother,1995,39(12):2770-2773
5[5]Sum PE,Lee VJ,Testa RT,et al.Glycylcyclines.Ⅰ.A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.J Med Chem,1993,37(1):184-188
6[6]Goldstein FW,Kitzis MD,Acar JF.N,N-Dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline,two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.Antimicrob Agents Chemother,1994,38(9):2218-2220
7[7]Nord C,Lindmark A,Person I.In vitro activity of DMG-Mino and DMG-Dmdot,two new glycylcyclines,against anaerobic bacteria.Eur J Clin Microbiol Infect Dis,1993,12(11):784-786
8[8]Toshiyuki Y,Yoichi H,Koichi I,et al.In vitro activity of telithromycin(HMR3647),a new ketolide,against clinical isolates of Mycoplasma pneumonia in Japan.Antimicrob Agents Chemother,2000,44(5):1381-1382
9[9]Petersen PJ,Jacobus NV,Weiss WJ,et al.In vitro and in vivo antibacterial activities of a novel glycylcycline,the 9-t-Butylglycylamido Derivative of minocycline(GAR-936).Antimicrob Agents Chemother,1999,43(4):738-744
